Analysts Set Regeneron Pharmaceuticals Inc (NASDAQ:REGN) PT at $390.93

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have been given a consensus recommendation of “Hold” by the twenty-one research firms that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $388.29.

REGN has been the topic of a number of research analyst reports. BMO Capital Markets set a $344.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Tuesday. BidaskClub raised shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Friday, June 21st. Credit Suisse Group dropped their price objective on shares of Regeneron Pharmaceuticals from $333.00 to $325.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Finally, Guggenheim raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $355.00 to $403.00 in a report on Monday, September 23rd.

Shares of REGN opened at $300.77 on Monday. The firm has a market capitalization of $31.94 billion, a PE ratio of 15.19, a price-to-earnings-growth ratio of 1.33 and a beta of 1.14. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.88 and a quick ratio of 3.11. Regeneron Pharmaceuticals has a 1-year low of $271.37 and a 1-year high of $442.00. The company’s fifty day moving average price is $286.11 and its 200-day moving average price is $315.65.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.60 by $0.69. The firm had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period in the previous year, the company earned $5.45 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 19.22 EPS for the current fiscal year.

In related news, major shareholder Sanofi sold 172,904 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. Insiders own 11.84% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Accurate Investment Solutions Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $31,000. HM Payson & Co. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $31,000. Thor Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $32,000. Coastal Capital Group Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $38,000. Finally, Focused Wealth Management Inc raised its position in shares of Regeneron Pharmaceuticals by 1,333.3% in the second quarter. Focused Wealth Management Inc now owns 129 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 120 shares during the period. Institutional investors own 66.54% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Do Tariffs Work?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit